Compare C3.ai Inc (AI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Summit Therapeutics Inc — how do they compare? C3.ai Inc trades at $10.1 (market cap $1.65B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 7.3× C3.ai Inc's market cap. Which is the better fit depends on your goals.
| AI | SMMT | |
|---|---|---|
Market Cap | $1.65B | $12.06B |
Sector | Technology | Health |
52-Week High | $19.66 | $26.98 |
52-Week Low | $7.76 | $12.55 |
Enterprise Value | $1.08B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.125, down 2.64% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported revenue of $389.06 million in 2025 but a net loss of $288.70 million, reflecting persistent unprofitability. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research (Business Wire, August 10, 2026), though CFO share sales and mixed earnings beats add complexity.
The stock faces significant fundamental challenges with negative margins and cash flow, but analyst consensus is mixed with a $10.20 price target near current levels. Investment opportunity hinges on AI platform adoption growth, while risks include sustained losses, competitive pressure, and high valuation multiples absent earnings.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
